Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: A prospective ECOG and Southwest Oncology Group correlative study on E4494

Clinical Cancer Research

Volumn 16, Issue 8, 2010, Pages 2435-2442

  Winter, Jane N ^a   Li, Shuli ^b   Aurora, Vikas ^a   Variakojis, Daina ^a   Nelson, Beverly ^a   Krajewska, Maryla ^c   Zhang, Lijun ^b   Habermann, Thomas M ^d   Fisher, Richard I ^e   Macon, William R ^d   Chhanabhai, Mukesh ^f   Felgar, Raymond E ^g   Hsi, Eric D ^h   Medeiros, L Jeffrey ⁱ   Weick, James K ^j   Weller, Edie A ^b   Melnick, Ari ^k   Reed, John C ^c   Horning, Sandra J ^l   Gascoyne, Randy D ^f  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BURNHAM INSTITUTE   (United States)

^d MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

^g UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^j Hematology Oncology Associates of the Palm Beaches   (United States)

^k WEILL CORNELL MEDICAL COLLEGE   (United States)

^l STANFORD UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TUMOR BIOPSY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE;

EID: 77950967521     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1219     Document Type: Article

References (50)

1. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-816 (Pubitemid 23346377)
2. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-825
3. Gartel AL, Tyner AL. Transcriptional regulation of the p21((WAF1/ CIP1)) gene. Exp Cell Res 1999;246:280-289 (Pubitemid 29393989)
4. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009;9:400-414
5. Phan RT, Saito M, Basso K, Niu H, Dalla-Favera R. BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat Immunol 2005;6:1054-1060 (Pubitemid 41486191)
6. Cerchietti LC, Polo JM, Da Silva GF, et al. Sequential transcription factor targeting for diffuse large B-cell lymphomas. Cancer Res 2008;68:3361-3369
7. Weiss RH, Borowsky AD, Seligson D, et al. p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. J Urol 2007;177:63-8; discussion 68-69 (Pubitemid 44879463)
8. Stein JP, Ginsberg DA, Grossfeld GD, et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998;90:1072-1079 (Pubitemid 28350272)
9. Shoji T, Tanaka F, Takata T, et al. Clinical significance of p21 expression in non-small-cell lung cancer. J Clin Oncol 2002;20:3865-3871 (Pubitemid 35424109)
10. Rose SL, Goodheart MJ, DeYoung BR, Smith BJ, Buller RE. p21 expression predicts outcome in p53-null ovarian carcinoma. Clin Cancer Res 2003;9:1028-1032
11. Roman-Gomez J, Castillejo JA, Jimenez A, et al. 5′ CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia. Blood 2002;99:2291-2296
12. Pinyol M, Hernandez L, Cazorla M, et al. Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood 1997;89:272-280 (Pubitemid 26428202)
13. Ichikawa A, Kinoshita T, Watanabe T, et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 1997;337:529-534 (Pubitemid 27352019)
14. Young KH, Weisenburger DD, Dave BJ, et al. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. Blood 2007;110:4396-4405
15. Chilosi M, Doglioni C, Magalini A, et al. p21/WAF1 cyclin-kinase inhibitor expression in non-Hodgkin's lymphomas: a potential marker of p53 tumor-suppressor gene function. Blood 1996;88:4012-4020 (Pubitemid 26383126)
16. Visco C, Canal F, Parolini C, et al. The impact of P53 and P21(waf1) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma. Haematologica 2006; 91:687-690 (Pubitemid 43799471)
17. Kramer MH, Hermans J, Parker J, et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol 1996;14:2131-2138 (Pubitemid 26230116)
18. Leroy K, Haioun C, Lepage E, et al. p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. Ann Oncol 2002;13:1108-1115
19. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242 (Pubitemid 34438862)
20. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-3127 (Pubitemid 46638950)
21. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-391
22. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003;101:4279-4284
23. Liu YY, Leboeuf C, Shi JY, et al. Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma. Blood 2007;110:339-344 (Pubitemid 47026852)
24. Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 2008;26:2717-2724
25. Winter JN, Weller EA, Horning SJ, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006;107:4207-4213 (Pubitemid 43801342)
26. Krajewski S, Bodrug S, Gascoyne R, Berean K, Krajewska M, Reed JC. Immunohistochemical analysis of Mcl-1 and Bcl-2 proteins in normal and neoplastic lymph nodes. Am J Pathol 1994;145:515-525 (Pubitemid 24285958)
27. Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002;99:1136-1143 (Pubitemid 34547064)
28. Farinha PSL, Skinnider B, Wu L, et al. Strong p53 expression is an independent predictor of outcome in de novo diffuse large B cell lymphoma (DLBCL) treated with either CHOP or CHOP-R. Blood 2006;108:abstract 812.
29. Izban KF, Alkan S, Singleton TP, Hsi ED. Multiparameter immunohistochemical analysis of the cell cycle proteins cyclin D1, Ki-67, p21WAF1, p27KIP1, and p53 in mantle cell lymphoma. Arch Pathol Lab Med 2000;124:1457-1462
30. Lunenberg Lymphoma Biomarker Consortium. First results of an international study to establish a new clinico-biological prognostic index for diffuse large B-cell lymphoma (DLBCL). Ann Oncol 2008; 19:iv100.
31. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
32. Lunceford JK, Davidian M, Tsiatis AA. Estimation of survival distributions of treatment policies in two-stage randomization designs in clinical trials. Biometrics 2002;58:48-57. (Pubitemid 34194487)
33. Wahed AS, Tsiatis AA. Optimal estimator for the survival distribution and related quantities for treatment policies in two-stage randomization designs in clinical trials. Biometrics 2004;60:124-133
34. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701-704 (Pubitemid 24036020)
35. Chen J, Jackson PK, Kirschner MW, Dutta A. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 1995; 374:386-388
36. De la Cueva E, Garcia-Cao I, Herranz M, et al. Tumorigenic activity of p21Waf1/Cip1 in thymic lymphoma. Oncogene 2006;25:4128-4132 (Pubitemid 44024876)
37. Roninson IB. Oncogenic functions of tumour suppressor p21(Waf1/ Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett 2002;179:1-14.
38. Wang YA, Elson A, Leder P. Loss of p21 increases sensitivity to ionizing radiation and delays the onset of lymphoma in atm-deficient mice. Proc Natl Acad Sci U S A 1997;94:14590-14595 (Pubitemid 28041418)
39. Mitsuuchi Y, Johnson SW, Selvakumaran M, Williams SJ, Hamilton TC, Testa JR. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cancer Res 2000;60:5390-5394
40. Li Y, Dowbenko D, Lasky LA. AKT/PKB phosphorylation of p21Cip/ WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. J Biol Chem 2002;277:11352-11361 (Pubitemid 34952901)
41. Rossig L, Badorff C, Holzmann Y, Zeiher AM, Dimmeler S. Glycogen synthase kinase-3 couples AKT-dependent signaling to the regulation of p21Cip1 degradation. J Biol Chem 2002;277:9684-9689 (Pubitemid 34968067)
42. Coleman ML, Marshall CJ, Olson MF. Ras promotes p21(Waf1/Cip1) protein stability via a cyclin D1-imposed block in proteasomemediated degradation. EMBO J 2003;22:2036-2046
43. Olson MF, Paterson HF, Marshall CJ. Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1. Nature 1998;394:295-299
44. Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4952-4957
45. Verhelle D, Corral LG, Wong K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007;67:746-755 (Pubitemid 46192215)
46. Piekarz RL, Robey RW, Zhan Z, et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 2004;103:4636-4643 (Pubitemid 38745996)
47. Matta H, Chaudhary PM. The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells. Cancer Biol Ther 2005;4:77-82. (Pubitemid 41350935)
48. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007;26:3629-3636 (Pubitemid 46842700)
49. Suzuki E, Umezawa K, Bonavida B. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis. Oncogene 2007;26: 6184-6193 (Pubitemid 47414382)
50. de Jong D, Rosenwald A, Chhanabhai M, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications - a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007;25:805-812 (Pubitemid 350002880)